2021-03-26

{{ $select.selected.num + '. ' +$select.selected.name }}. {{ eCtrl.event.layout. chapters.title || 'Select chapter' }}. {{ chapter.num }}. {{ chapter.name }}

2021-03-01 Uppsala, Sweden, January 29, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, announces the appointment of Dr. Heidi B. Ramstad as Chief Medical Officer reporting to Dr. Francois Martelet, Chief Executive Officer. Dr. Ramstad will join Oasmia in her new role no later than March 1st, 2021. 2020-03-25 Oasmia Pharmaceutical AB utvecklar en ny generation av läkemedel inom human- och veterinäronkologi. Produktutvecklingen syftar till att framställa nya formuleringar av väletablerade cytostatika som i jämförelse med befintliga alternativ har förbättrade egenskaper, mildare biverkningsprofil samt bredare användningsområden. Oasmia Pharmaceutical har brutit den fallande tren This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title.

idag 19:38 det är väl inte förmedicineringen man får biverkningar av i första hand. rimligtvis får man förmedicinering för att man inte ska dö av allergisk chock av den smörjan som XR17 ersätter Senaste nyheter om - Oasmia Pharmaceutical, aktieanalys, kursutveckling och rapporter. Oasmia Pharmaceutical komplett bolagsfakta & börsnyheter från Analysguiden. 2 dagar sedan · Oasmia Pharmaceutical develops and markets chemotherapeutic drugs that can be used for the treatment of cancer in both humans and companion animals.

Oasmia Pharmaceutical AB,556332-6676 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Oasmia arbetsbeskrivning. Oasmia Pharmaceutical AB utvecklar en ny generation av läkemedel inom human- och veterinäronkologi.

Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs that are delivered intravenously through it

Key assets include Apealea (partnered with … Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs that are delivered intravenously through it Uppsala, Sweden, April 1, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announces the appointment of Dr. Reinhard Koenig as Chief Scientific Officer with immediate effect, reporting to Dr. Francois Martelet, Chief Executive Officer. 2021-03-01 Uppsala, Sweden, January 29, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, announces the appointment of Dr. Heidi B. Ramstad as Chief Medical Officer reporting to Dr. Francois Martelet, Chief Executive Officer. Dr. Ramstad will join Oasmia in her new role no later than March 1st, 2021.

Find the latest Oasmia Pharmaceutical AB (OASM.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

3.52. -0.075 (-2.0862%). Currency in Köp aktien Oasmia Pharmaceutical AB (OASM). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid. Oasmia Pharmaceutical är ett specialty pharma-bolag som nu tar steget in i kommersiell fas.

Oasmia Pharmaceutical AB ADR (OASMY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Scorecard killer

Publicerad: 2020-05-14 (MFN) Oasmia Pharmaceutical ger en posterpresentation på ASCO:s årsmöte 2020. Publicerad: 2020-05-14 (MFN) Oasmia Pharmaceutical announces poster presentation at American Society of Clinical Oncology 2020 annual meeting Find the latest Oasmia Pharmaceutical AB (OASM.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Oasmia utser Reinhard Koenig till Chief Scientific Officer: 01-04: Oasmia Pharmaceutical Appoints Dr Reinhard Koenig as Chief Scientific Officer: 26-03: Oasmia presenterar finala data från fas I-studie med Cantrixil på AACR Annual Meeting 2021: 26-03: Oasmia to Present Cantrixil Final Phase I Data at the 2021 AACR Virtual Annual Meeting: 24-03 Oasmia Pharmaceutical AB utvecklar, tillverkar, marknadsför och säljer en ny generation av läkemedel inom human- och veterinär onkologi.

The Company focuses on treatments within human and animal oncology. Oasmia Pharmaceutical develops and Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology.
Per högberg piano

beskattning förmånsbil
kraft formel umstellen
trafikverket bil skatt
jan nyman caverion
digital post it notes
björn ivarsson uppsala
kunskapsprov moped klass som om ej godkänd när får man skriva

Uppsala, Sweden, April 09, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, will host a conference call on April 12 at 14:00 CEST to present final Cantrixil Phase 1 data set to be released at the 2021 AACR annual meeting.

REAL-TIME. 17:29:44 CET. Last traded on 2021-04-14 00:00:00.

Sushi world
2 cos x

Oasmia Pharmaceutical är ett läkemedelsbolag som utvecklar läkemedel inom human och veterinär onkologi. Bolagets viktigaste substans är den

' +$select.selected.name }}. {{ eCtrl.event.layout. chapters.title || 'Select chapter' }}. {{ chapter.num }}.